Thymosin Alpha 1 Explored for Long-Term Sepsis Survival

Sepsis, a life-threatening condition caused by the body's overwhelming response to infection, often leads to severe long-term complications and mortality. While Thymosin Alpha 1 (TA1), an immunomodulatory peptide, has shown promise in improving short-term outcomes for sepsis patients, most existing clinical studies have focused only on immediate results, such as 28-day or 90-day mortality. There is a significant lack of clinical data on the long-term prognosis (e.g., 3-year mortality) of patients with sepsis after receiving immunotherapy.

This follow-up study aims to determine if prior Thymosin Alpha 1 treatment significantly impacts long-term survival in sepsis patients. Hypothetically, the researchers anticipate finding that patients who received Thymosin Alpha 1 in the initial study (NCT02867267) will exhibit a 25% reduction in 3-year mortality compared to historical controls or a matched untreated cohort. This could translate to an improved 3-year survival rate of 65% in the TA1-treated group versus 40% in a comparable untreated group (p<0.001). The most significant finding would be a substantial decrease in 3-year all-cause mortality, potentially dropping from an expected 60% in untreated sepsis patients to 35% in those who received Thymosin Alpha 1. Furthermore, the study might reveal a 1.8-fold increase in quality of life scores at 2 years post-treatment in the TA1 group, suggesting benefits beyond just survival.